KEGG   PATHWAY: mcc05211
Entry
mcc05211                    Pathway                                
Name
Renal cell carcinoma - Macaca mulatta (rhesus monkey)
Description
Renal cell cancer (RCC) accounts for ~3% of human malignancies and its incidence appears to be rising. Although most cases of RCC seem to occur sporadically, an inherited predisposition to renal cancer accounts for 1-4% of cases. RCC is not a single disease, it has several morphological subtypes. Conventional RCC (clear cell RCC) accounts for ~80% of cases, followed by papillary RCC (10-15%), chromophobe RCC (5%), and collecting duct RCC (<1%). Genes potentially involved in sporadic neoplasms of each particular type are VHL, MET, BHD, and FH respectively. In the absence of VHL, hypoxia-inducible factor alpha (HIF-alpha) accumulates, leading to production of several growth factors, including vascular endothelial growth factor and platelet-derived growth factor. Activated MET mediates a number of biological effects including motility, invasion of extracellular matrix, cellular transformation, prevention of apoptosis and metastasis formation. Loss of functional FH leads to accumulation of fumarate in the cell, triggering inhibition of HPH and preventing targeted pVHL-mediated degradation of HIF-alpha. BHD mutations cause the Birt-Hogg-Dube syndrome and its associated chromophobe, hybrid oncocytic, and conventional (clear cell) RCC.
Class
Human Diseases; Cancer: specific types
Pathway map
mcc05211  Renal cell carcinoma
mcc05211

Organism
Macaca mulatta (rhesus monkey) [GN:mcc]
Gene
704678  HIF1A; hypoxia-inducible factor 1-alpha isoform X4 [KO:K08268]
714641  EPAS1; endothelial PAS domain-containing protein 1 isoform X1 [KO:K09095]
713410  EGLN1; egl nine homolog 1 isoform X1 [KO:K09592] [EC:1.14.11.29]
717342  EGLN3; egl nine homolog 3 [KO:K09592] [EC:1.14.11.29]
703083  EGLN2; egl nine homolog 2 [KO:K09592] [EC:1.14.11.29]
114674212  EGLN2; LOW QUALITY PROTEIN: egl nine homolog 2 [KO:K09592] [EC:1.14.11.29]
106996285  VHL; von Hippel-Lindau disease tumor suppressor isoform X1 [KO:K03871]
698922  ELOC; transcription elongation factor B polypeptide 1 [KO:K03872]
100428355  elongin-C-like [KO:K03872]
715218  elongin-B [KO:K03873]
700034  ELOB; elongin-B [KO:K03873]
710252  RBX1; E3 ubiquitin-protein ligase RBX1 [KO:K03868] [EC:2.3.2.32]
698384  CUL2; cullin-2 [KO:K03870]
715971  ARNT; aryl hydrocarbon receptor nuclear translocator isoform X1 [KO:K09097]
712786  ARNT2; aryl hydrocarbon receptor nuclear translocator 2 isoform X1 [KO:K15589]
706258  EP300; histone acetyltransferase p300 [KO:K04498] [EC:2.3.1.48]
704331  CREBBP; CREB-binding protein [KO:K04498] [EC:2.3.1.48]
698931  SLC2A1; solute carrier family 2, facilitated glucose transporter member 1 [KO:K07299]
574209  VEGFA; vascular endothelial growth factor A isoform 1 precursor [KO:K05448]
106992315  TGFB1; transforming growth factor beta-1 proprotein isoform X2 [KO:K13375]
707540  TGFB2; transforming growth factor beta-2 precursor [KO:K13376]
703239  TGFB3; transforming growth factor beta-3 precursor [KO:K13377]
703173  PDGFB; platelet-derived growth factor subunit B [KO:K17386]
613031  TGFA; protransforming growth factor alpha isoform X2 [KO:K08774]
708316  HGF; hepatocyte growth factor isoform X3 [KO:K05460]
704562  MET; hepatocyte growth factor receptor precursor [KO:K05099] [EC:2.7.10.1]
700367  GAB1; GRB2-associated-binding protein 1 [KO:K09593]
716098  PIK3CB; phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform isoform X1 [KO:K00922] [EC:2.7.1.153]
709959  PIK3CA; phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform [KO:K00922] [EC:2.7.1.153]
710552  PIK3CD; phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform isoform X1 [KO:K00922] [EC:2.7.1.153]
707310  PIK3R3; phosphatidylinositol 3-kinase regulatory subunit gamma [KO:K02649]
719367  PIK3R2; phosphatidylinositol 3-kinase regulatory subunit beta [KO:K02649]
698996  PIK3R1; phosphatidylinositol 3-kinase regulatory subunit alpha [KO:K02649]
714717  AKT3; RAC-gamma serine/threonine-protein kinase [KO:K04456] [EC:2.7.11.1]
697747  AKT1; RAC-alpha serine/threonine-protein kinase [KO:K04456] [EC:2.7.11.1]
700591  AKT2; RAC-beta serine/threonine-protein kinase [KO:K04456] [EC:2.7.11.1]
717740  BAD; bcl2-associated agonist of cell death [KO:K02158]
696584  CRKL; crk-like protein [KO:K04438]
701185  CRK; adapter molecule crk isoform X1 [KO:K04438]
715272  RAPGEF1; rap guanine nucleotide exchange factor 1 isoform X1 [KO:K06277]
704404  RAP1A; ras-related protein Rap-1A [KO:K04353]
718171  RAP1B; ras-related protein Rap-1b [KO:K07836]
693750  LOW QUALITY PROTEIN: ras-related protein Rap-1b [KO:K07836]
712044  PTPN11; tyrosine-protein phosphatase non-receptor type 11 [KO:K07293] [EC:3.1.3.48]
702041  GRB2; growth factor receptor-bound protein 2 [KO:K04364]
713777  SOS1; son of sevenless homolog 1 isoform X1 [KO:K03099]
705601  SOS2; son of sevenless homolog 2 [KO:K03099]
698830  HRAS; GTPase HRas [KO:K02833]
707977  KRAS; GTPase KRas [KO:K07827]
709089  NRAS; GTPase NRas [KO:K07828]
707169  ARAF; serine/threonine-protein kinase A-Raf [KO:K08845] [EC:2.7.11.1]
693554  BRAF; serine/threonine-protein kinase B-raf isoform X1 [KO:K04365] [EC:2.7.11.1]
694725  RAF1; RAF proto-oncogene serine/threonine-protein kinase [KO:K04366] [EC:2.7.11.1]
710415  MAP2K1; dual specificity mitogen-activated protein kinase kinase 1 [KO:K04368] [EC:2.7.12.2]
721821  MAP2K2; dual specificity mitogen-activated protein kinase kinase 2 isoform X1 [KO:K04369] [EC:2.7.12.2]
708938  MAPK3; mitogen-activated protein kinase 3 isoform X1 [KO:K04371] [EC:2.7.11.24]
698569  MAPK1; mitogen-activated protein kinase 1 [KO:K04371] [EC:2.7.11.24]
714697  ETS1; protein C-ets-1 isoform X1 [KO:K02678]
716452  JUN; transcription factor AP-1 [KO:K04448]
717755  RAC1; ras-related C3 botulinum toxin substrate 1 isoform X1 [KO:K04392]
707637  CDC42; cell division control protein 42 homolog [KO:K04393]
698585  PAK1; serine/threonine-protein kinase PAK 1 isoform X5 [KO:K04409] [EC:2.7.11.1]
710314  PAK2; serine/threonine-protein kinase PAK 2 [KO:K04410] [EC:2.7.11.1]
706217  PAK3; serine/threonine-protein kinase PAK 3 isoform X1 [KO:K05733] [EC:2.7.11.1]
696676  PAK4; serine/threonine-protein kinase PAK 4 isoform X1 [KO:K05734] [EC:2.7.11.1]
719458  PAK5; serine/threonine-protein kinase PAK 7 [KO:K05736] [EC:2.7.11.1]
701589  PAK6; serine/threonine-protein kinase PAK 6 [KO:K05735] [EC:2.7.11.1]
718660  PRCC; proline-rich protein PRCC [KO:K13105]
712161  TFE3; transcription factor E3 [KO:K09105]
719199  CDKN1A; cyclin-dependent kinase inhibitor 1 [KO:K06625]
707542  FH; fumarate hydratase, mitochondrial [KO:K01679] [EC:4.2.1.2]
698082  FLCN; folliculin [KO:K09594]
Compound
C00007  Oxygen
C00122  Fumarate
C00149  (S)-Malate
Reference
  Authors
Cohen HT, McGovern FJ.
  Title
Renal-cell carcinoma.
  Journal
N Engl J Med 353:2477-90 (2005)
DOI:10.1056/NEJMra043172
Reference
  Authors
Pavlovich CP, Schmidt LS.
  Title
Searching for the hereditary causes of renal-cell carcinoma.
  Journal
Nat Rev Cancer 4:381-93 (2004)
DOI:10.1038/nrc1364
Reference
  Authors
Linehan WM, Walther MM, Zbar B.
  Title
The genetic basis of cancer of the kidney.
  Journal
J Urol 170:2163-72 (2003)
DOI:10.1097/01.ju.0000096060.92397.ed
Reference
  Authors
Kim WY, Kaelin WG.
  Title
Role of VHL gene mutation in human cancer.
  Journal
J Clin Oncol 22:4991-5004 (2004)
DOI:10.1200/JCO.2004.05.061
Reference
  Authors
Sudarshan S, Linehan WM, Neckers L.
  Title
HIF and fumarate hydratase in renal cancer.
  Journal
Br J Cancer 96:403-7 (2007)
DOI:10.1038/sj.bjc.6603547
Reference
  Authors
Sudarshan S, Pinto PA, Neckers L, Linehan WM.
  Title
Mechanisms of disease: hereditary leiomyomatosis and renal cell cancer--a distinct form of hereditary kidney cancer.
  Journal
Nat Clin Pract Urol 4:104-10 (2007)
DOI:10.1038/ncpuro0711
Reference
  Authors
Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF.
  Title
Met, metastasis, motility and more.
  Journal
Nat Rev Mol Cell Biol 4:915-25 (2003)
DOI:10.1038/nrm1261
Reference
  Authors
Muller-Hocker J, Babaryka G, Schmid I, Jung A
  Title
Overexpression of cyclin D1, D3, and p21 in an infantile renal carcinoma with Xp11.2 TFE3-gene fusion.
  Journal
Pathol Res Pract 204:589-97 (2008)
DOI:10.1016/j.prp.2008.01.010
Reference
  Authors
Bodmer D, van den Hurk W, van Groningen JJ, Eleveld MJ, Martens GJ, Weterman MA, van Kessel AG.
  Title
Understanding familial and non-familial renal cell cancer.
  Journal
Hum Mol Genet 11:2489-98 (2002)
DOI:10.1093/hmg/11.20.2489
Reference
  Authors
Kauffman EC, Ricketts CJ, Rais-Bahrami S, Yang Y, Merino MJ, Bottaro DP, Srinivasan R, Linehan WM
  Title
Molecular genetics and cellular features of TFE3 and TFEB fusion kidney cancers.
  Journal
Nat Rev Urol 11:465-75 (2014)
DOI:10.1038/nrurol.2014.162
Reference
  Authors
Skalsky YM, Ajuh PM, Parker C, Lamond AI, Goodwin G, Cooper CS
  Title
PRCC, the commonest TFE3 fusion partner in papillary renal carcinoma is associated with pre-mRNA splicing factors.
  Journal
Oncogene 20:178-87 (2001)
DOI:10.1038/sj.onc.1204056
Reference
  Authors
Medendorp K, van Groningen JJ, Vreede L, Hetterschijt L, Brugmans L, van den Hurk WH, van Kessel AG
  Title
The renal cell carcinoma-associated oncogenic fusion protein PRCCTFE3 provokes p21 WAF1/CIP1-mediated cell cycle delay.
  Journal
Exp Cell Res 315:2399-409 (2009)
DOI:10.1016/j.yexcr.2009.04.022
Related
pathway
mcc00020  Citrate cycle (TCA cycle)
mcc04010  MAPK signaling pathway
mcc04066  HIF-1 signaling pathway
mcc04120  Ubiquitin mediated proteolysis
mcc04350  TGF-beta signaling pathway
mcc04370  VEGF signaling pathway
KO pathway
ko05211   
LinkDB

DBGET integrated database retrieval system